GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Dynavax Technologies Corp (FRA:DYF1) » Definitions » Shiller PE Ratio

Dynavax Technologies (FRA:DYF1) Shiller PE Ratio : (As of Jun. 09, 2024)


View and export this data going back to 2004. Start your Free Trial

What is Dynavax Technologies Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Dynavax Technologies Shiller PE Ratio Historical Data

The historical data trend for Dynavax Technologies's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dynavax Technologies Shiller PE Ratio Chart

Dynavax Technologies Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Dynavax Technologies Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Dynavax Technologies's Shiller PE Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Dynavax Technologies's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dynavax Technologies's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Dynavax Technologies's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Dynavax Technologies's Shiller PE Ratio falls into.



Dynavax Technologies Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Dynavax Technologies's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Dynavax Technologies's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.064/131.7762*131.7762
=-0.064

Current CPI (Mar. 2024) = 131.7762.

Dynavax Technologies Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -0.692 100.560 -0.907
201409 -0.877 100.428 -1.151
201412 -0.689 99.070 -0.916
201503 -0.896 99.621 -1.185
201506 -0.713 100.684 -0.933
201509 -0.731 100.392 -0.960
201512 -0.643 99.792 -0.849
201603 -0.629 100.470 -0.825
201606 -0.668 101.688 -0.866
201609 -0.802 101.861 -1.038
201612 -0.531 101.863 -0.687
201703 -0.561 102.862 -0.719
201706 -0.365 103.349 -0.465
201709 -0.319 104.136 -0.404
201712 -0.380 104.011 -0.481
201803 -0.511 105.290 -0.640
201806 -0.539 106.317 -0.668
201809 -0.557 106.507 -0.689
201812 -0.563 105.998 -0.700
201903 -0.549 107.251 -0.675
201906 -0.584 108.070 -0.712
201909 -0.445 108.329 -0.541
201912 -0.396 108.420 -0.481
202003 -0.226 108.902 -0.273
202006 -0.471 108.767 -0.571
202009 0.034 109.815 0.041
202012 -0.115 109.897 -0.138
202103 0.008 111.754 0.009
202106 0.017 114.631 0.020
202109 -0.204 115.734 -0.232
202112 0.487 117.630 0.546
202203 0.200 121.301 0.217
202206 0.823 125.017 0.867
202209 0.434 125.227 0.457
202212 0.425 125.222 0.447
202303 -0.177 127.348 -0.183
202306 0.028 128.729 0.029
202309 0.094 129.860 0.095
202312 0.000 129.419 0.000
202403 -0.064 131.776 -0.064

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Dynavax Technologies  (FRA:DYF1) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Dynavax Technologies Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Dynavax Technologies's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Dynavax Technologies (FRA:DYF1) Business Description

Traded in Other Exchanges
Address
2100 Powell Street, Suite 900, Emeryville, CA, USA, 94608
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.

Dynavax Technologies (FRA:DYF1) Headlines

No Headlines